Associated Papers
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
37579140 (PubMed )
Supplement: pnas.2304184120.sapp.pdf
Molecular and clinicopathologic characterization of pediatric histiocytoses.
Hélias-Rodzewicz Z et al.
American Journal of Hematology, 2023
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S et al.
Molecular Cancer Therapeutics, 2023
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
32283832 (PubMed )
Supplement: cancers-12-00927-s001.pdf
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H et al.
Oncogene, 2017
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
Van Allen EM et al.
Cancer Discovery, 2014
A bipartite mechanism for ERK2 recognition by its cognate regulators and substrates.
Zhang J et al.
The Journal of Biological Chemistry, 2003
Select a paper to view details